Its indications include metastatic ErbB2 positive breast cancer, non-small cell lung cancer (NSCLC), and gastric or gastroesophageal junction adenocarcinoma (FDALabel, 2022c; Van Cutsem et al., 2023). Here, ERBB2 is linked to breast carcinoma.